Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

NCT04013672 is registered in ClinicalTrials.gov with David Peereboom as lead sponsor.

NCT NCT04013672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04013672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Lead sponsor
David Peereboom
Phase
Phase 2
Overall status
Completed
Start date
March 19, 2020
Completion date
February 16, 2022
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma